.RESEARCH HIGHLIGHT.16 Oct 2024.
In the NIAGARA trial, the addition of perioperative durvalumab to common treatment for muscle-invasive sac cancer enhanced event-free and also generally survival, noting a brand new therapy possibility for this health condition.